Wells Pharma

What Wells Pharma does

Wells Pharma is an FDA-registered 503B outsourcing facility founded in 2020 and headquartered in the Texas Medical Center corridor of Houston, Texas. The company manufactures and distributes ready-to-use sterile compounded medications to hospitals and ambulatory surgery centers across 48 U.S. states. Its portfolio of 60+ products is organized into OR syringes, antibiotics (ceFAZolin, Vancomycin), pain/PCA preparations (Fentanyl, Morphine, Ketamine, Midazolam), epidural and nerve block products (Ropivacaine, Lidocaine), standard IV admixtures, and selected non-sterile products, with drug-shortage medications positioned as a strategic category. Manufacturing occurs in ISO-classified cleanroom infrastructure (currently 10 operational ISO-5 vertical laminar flow hoods, two ISO 7 cleanrooms, and one ISO 8 API dispensing suite, with 14 additional hoods being commissioned) operating under cGMP and USP <797>, <788>, and <85> standards, with DEA registration permitting compounding of Schedule II controlled substances such as Fentanyl and Morphine.

The business model is B2B direct sales of compounded sterile medications through a dedicated enterprise field sales team of regional AVPs organized by territory and an online ordering portal for healthcare providers. Pricing is quote-based and not publicly disclosed. Wells Pharma is differentiated primarily via its regulatory status, quality release testing on 100% of batches, 48-hour standard lead times, and a stated "5Cs" framework (Confidence in Quality, Customer Service, Comprehensive Portfolio, Consistent Supply, Competitive Value). The company is privately held and operating; ownership is not publicly disclosed and no parent company, subsidiaries, or external funding rounds are identified in the available sources. Leadership includes President and CFO Andy Corbin (previously led a 42,000 sq ft 503B build-out), VP of Quality Carissa Imrecke, SVP of Sales and Marketing Stan Pflueger (credited with 213% average annual revenue growth since 2021), and VP of Sales David Koch.

Name

Wells Pharma

Legal name

Wells Pharma

Website

https://wellspharmatx.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

51–100 employees

Short description

Wells Pharma is a Houston-based FDA-registered 503B outsourcing facility that manufactures and distributes ready-to-use sterile compounded medications to hospitals and ambulatory surgery centers across 48 U.S. states.

Ownership category

akta.pro rank

Product category

503B Compounded Sterile Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Compounding Pharmacies (Sterile/Non-Sterile) (HLAFALAE)

akta.pro secondary industry

Controlled Substances & Compliance-Focused Pharmaceutical Distributors (HLAIAJAN)

Keywords

• 503B outsourcing facility
• Sterile compounded medications
• Prefilled syringes
• Hospital pharmacy supply
• CGMP pharmaceutical manufacturing

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Compounded Sterile Medications Sales: B2B sales of FDA-registered 503B compounded sterile medications to hospitals and surgery centers. Products include ready-to-use prefilled syringes, IV admixtures, sterile admixtures, and drug-shortage medications. Revenue generated through direct product sales with order fulfillment through online portal and sales team coordination.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Wells Pharma operates an FDA-registered 503B outsourcing facility that manufactures and sells ready-to-use sterile compounded medications, including prefilled syringes, IV admixtures, antibiotics (ceFAZolin, Vancomycin), anesthesia agents, neuromuscular blockers, vasopressors, pain/PCA preparations, epidural and nerve block products, and drug-shortage medications, primarily to U.S. hospitals and ambulatory surgery centers. All products are cGMP-compliant, produced under USP <797>, <788>, and <85> standards, sterility and potency tested, and shipped to 48 states with most orders fulfilled within 48 hours.

Product overview

Wells Pharma is an FDA-registered 503B outsourcing facility providing a portfolio of ready-to-use sterile compounded medications to hospitals and surgery centers nationwide. The product portfolio includes: OR Syringes (anesthetic agents including Fentanyl, Ketamine, Midazolam; neuromuscular blockers including Rocuronium, Succinylcholine; vasopressors including Phenylephrine, Ephedrine; anticholinergics including Atropine, Glycopyrrolate; reversal agents including Neostigmine; beta-blockers including Esmolol; and local anesthetics including Lidocaine); Antibiotics (ceFAZolin and Vancomycin in multiple strengths and formulations); Pain/PCA Products (Fentanyl combinations with Ropivacaine, Morphine prefilled syringes, Ketamine, and Midazolam); Epidural & Nerve Block Preparations (Ropivacaine 0.2% and combination products); IV Admixtures (antibiotic bags in 0.9% Sodium Chloride); and Non-Sterile Products (Indomethacin suppository). Additional offerings include Pre-Filled Arrow Pain Pumps and Drug Shortage Medications. All sterile products are manufactured under cGMP compliance with sterility, endotoxin, and potency testing before release.

Differentiator

Problem solved

Functional benefit

Products and services

• OR Syringes Portfolio Ready-to-use prefilled syringes designed to support operating room efficiency by reducing on-site preparation steps; includes anesthesia agents, neuromuscular blockers, vasopressors, reversal agents, anticholinergics, beta-blockers, and local anesthetics with sterility, particulate, and potency testing.
• Antibiotic Preparations (ceFAZolin and Vancomycin) Sterile antibiotic preparations of ceFAZolin (1gm, 2gm, 3gm) and Vancomycin (1gm–2gm) in 0.9% Sodium Chloride bags and Sterile Water for Injection syringes, designed to support antimicrobial stewardship initiatives and standardized treatment protocols in hospitals.
• Pain / PCA Preparations (Fentanyl, Ketamine, Midazolam, Morphine, Lidocaine) Sterile prefilled syringes and IV bags for Patient-Controlled Analgesia and pain management including opioid analgesics (Fentanyl 50mcg–2,500mcg, Morphine 2mg), benzodiazepines (Midazolam 50mg/50mL–100mg/100mL), anesthetics (Ketamine 50mg, 100mg), and local anesthetics (Lidocaine 60mg, 100mg).
• Epidural & Nerve Block Preparations Sterile prefilled syringes including Ropivacaine 0.2% in 0.9% Sodium Chloride, used for regional anesthesia and epidural procedures, supporting anesthesia protocols requiring precision and consistency.
• IV Admixtures and Standard Services Sterile IV preparations including antibiotic admixtures (ceFAZolin, Vancomycin), analgesic combinations, hypertonic Dextrose 50% in Sterile Water for Injection, and other sterile-to-sterile formulations provided in 0.9% Sodium Chloride bags to reduce pharmacy compounding burden.
• Pre-Filled Arrow Pain Pumps Ready-to-use pre-filled pain management infusion pumps designed for Patient-Controlled Analgesia (PCA) delivery systems, supporting postoperative pain management protocols in hospitals and surgery centers.
• Non-Sterile Products (Indomethacin Suppository) Non-sterile NSAID preparation of Indomethacin 100mg suppository for anti-inflammatory and analgesic therapy in conditions requiring rectal administration.
• Drug Shortage Medications Supply Critical medications supplied during national drug shortages and supply disruptions, including proactive inventory planning and scalable production to help hospitals and surgery centers maintain continuity of care.

Quantifiable outcome

• 100% batches evaluated for sterility, particulate levels, and potency
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• QuVa Pharma: QuVa Pharma is an FDA-registered 503B outsourcing facility producing ready-to-use sterile compounded preparations for hospitals. It is one of the closest direct competitors to Wells Pharma in the hospital 503B sterile admixture and prefilled syringe market.
• SCA Pharma: SCA Pharma is one of the largest FDA-registered 503B outsourcing facilities producing sterile admixtures and prefilled syringes for hospitals and surgery centers. It is explicitly named as a key Wells Pharma peer and competes head-to-head across OR syringe, pain management, and antibiotic product lines.
• Nephron Pharmaceuticals Corporation: Nephron operates an FDA-registered 503B outsourcing division alongside generic manufacturing, supplying sterile prefilled syringes and IV bags to hospitals. Wells Pharma explicitly identifies Nephron as a key 503B peer competing in the same nationwide hospital market.
• Athenex: Athenex operated a 503B outsourcing facility producing sterile compounded medications for hospitals. Wells Pharma lists Athenex as a key 503B peer; Athenex's recent strategic restructuring makes it a comparable but distressed reference point for facility-level economics.
• Olympia Pharmacy: Olympia Pharmacy operates an FDA-registered 503B outsourcing facility providing sterile compounded preparations to hospitals and surgery centers. It is explicitly listed by Wells Pharma as a key market peer, with overlapping OR syringe and perioperative product lines.
• Central Admixture Pharmacy Services (CAPS): CAPS is one of the largest 503B outsourcing networks, providing sterile admixture and prefilled syringe services to hospital systems nationwide. It is a direct competitor to Wells Pharma in the hospital outsourced sterile compounding category.
• Leiters Health: Leiters is an FDA-registered 503B outsourcing facility producing ready-to-administer sterile preparations, including ophthalmic and anesthesia products. It is comparable to Wells Pharma as a hospital-focused 503B outsourcer with cGMP operations.
• Fagron Compounding Pharmacies: Fagron operates compounding pharmacy operations serving hospitals and clinics, including sterile and non-sterile preparations. It is explicitly named by Wells Pharma as a key peer and overlaps on hospital custom-compounded product offerings.

Emerging players

• STAQ Pharma: STAQ Pharma is an FDA-registered 503B outsourcing facility producing sterile injectable preparations for hospitals. It is a smaller, emerging 503B competitor that overlaps with Wells Pharma's hospital customer base and ready-to-use product positioning.

Broad incumbents

• ICU Medical (PharmaMedium): ICU Medical acquired Pharmedium Services, one of the largest 503B outsourcing operations in the US. As a broad medical device and infusion therapy incumbent, ICU Medical represents a scaled 503B competitor and potential strategic acquirer for Wells Pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/WellsPharma
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/wells-pharma
• Instagraminstagram.com/wellspharma

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wells Pharma